Genmab traded at 3,448.00 this Friday November 13th, decreasing 82.00 or 2.32 percent since the previous trading session. Looking back, over the last four weeks, Genmab lost 38.98 percent. Over the last 12 months, its price rose by 76.50 percent. Looking ahead, we forecast Genmab to be priced at 3,319.39 by the end of this quarter and at 2,961.63 in one year, according to Trading Economics global macro models projections and analysts expectations.
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.